PharmaMar Will Present the Results of the Phase I/II Study With Lurbinectedin in Combination With Doxorubicin in Relapsed Small-cell Lung Cancer During the IASLC World Conference

Thursday, September 6, 2018 Cancer News
Email Print This Page Comment bookmark
Font : A-A+

MADRID, September 6, 2018 /PRNewswire/ --

  • The results are from Cohort B of
    the Phase I/II Study in patients with small-cell lung cancer, a study that predated the Phase III ATLANTIS Study
    at the same dose level in a similar population 
  • An Overall Survival (OS) of 10.2 months was observed, rising to 11.5 months in platinum-sensitive patients 
  • The data will be presented at the World Conference on Lung Cancer held in Toronto (Canada) at the IASLC 2018 

PharmaMar (MCE: PHM) announces that the International Association for the Study of Lung Cancer (IASLC) has released today the abstracts for presentation during the Conference that will take place from the 23rd to the 26th of September in Toronto (Canada). The abstract to be presented by PharmaMar shows Overall Survival (OS) data obtained from the Phase I/II Study of lurbinectedin in combination with doxorubicin for the treatment of relapsed small-cell lung cancer.

     (Logo: http://mma.prnewswire.com/media/624563/PharmaMar_Logo.jpg )

In the study, PharmaMar observed Overall Survival (OS) of 10.2 months in patients treated with lurbinectedin in combination with doxorubicin, and OS of 11.5 months in platinum-sensitive patients (patients with a chemotherapy free interval (CTFI) of more than 90 days) in patients treated with lurbinectedin in combination with doxorubicin. We believe that the OS periods observed in this trial is are more favorable than those seen in historical trials of the primary treatments used for second line in small-cell lung cancer, as topotecan or the CAV combination (cyclophosphamide, adriamycin, vincristine).

This multicenter, Phase I/II Clinical Study enrolled patients with relapsed small-cell lung cancer (n=27) in cohort B, using the dose 2mg/m[2] of lurbinectedin + 40mg/m[2] of doxorubicin, the same dose that is being evaluated in the Phase III randomized ATLANTIS study in a similar population. In both cases the refractory patients are excluded, meaning those patients that have relapsed or have suffered a progression of the disease up to 30 days after first line treatment (CTFI <30 days).

Following the receipt of early data from this study in August 2016 PharmaMar initiated the pivotal Phase III ATLANTIS Study, that reached in July 2018 its recruitment objective of 600 patients. The trial recruited patients at 160 centers in 20 countries, and results are expected at the end of 2019.

The abstract with all this data is available on the Congress web page: https://library.iaslc.org

  • Overall survival with lurbinectedin plus doxorubicin in relapsed SCLC. Results from an expansion cohort of a phase Ib trial. 

Poster: P1.12-20. Monday, September 24th, 2018, from 16:45 to 18:00. Exhibit Hall.

Lead author: Martin Forster, MD. University College of London Hospital and UCL Cancer Institute, London, UK

About lurbinectedin  Lurbinectedin (PM1183) is a compound under clinical investigation. It is an inhibitor of RNA polymerase II. This enzyme is essential for the transcription process that is over-activated in tumors with transcription addiction.

About PharmaMar    Headquartered in Madrid, PharmaMar is a biopharmaceutical company, focused on oncology and committed to research and development which takes its inspiration from the sea to discover molecules with antitumor activity. It is a company that seeks innovative products to provide healthcare professionals with new tools to treat cancer. Its commitment to patients and to research has made it one of the world leaders in the discovery of antitumor drugs of marine origin.

PharmaMar has a pipeline of drug candidates and a robust R&D oncology program. With subsidiaries in Germany, Italy, France, Switzerland, Belgium, Austria and the United States. PharmaMar wholly owns other companies: GENOMICA, a molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi); and two chemical enterprises, Zelnova Zeltia and Xylazel.

To learn more about PharmaMar, please visit us at http://www.pharmamar.com.

Disclaimer  This document is a press release, not a prospectus. This document does not constitute or form part of an offering or invitation to sell or a solicitation to purchase, offer or subscribe shares of the company. Moreover, no reliance should be placed upon this document for any investment decision or contract and it does not constitute a recommendation of any type with regard to the shares of the company.

Twitter Facebook LinkedIn Instagram YouTube   

Or please visit our website at http://www.pharmamar.com

Media Contact:  Alfonso Ortín Communications Director aortin@pharmamar.com Mobile: +34-609-493-127

Miguel Martínez-Cava Digital Communication Manager mmartinez-cava@pharmamar.com Mobile: +34-606-597-464 Phone: +34-918-466-000

Investor Relations:  Phone: +34-914-444-500 / +34-902-10-19-00 Email: investorrelations@pharmamar.com

SOURCE PharmaMar



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store